EVOTAZ

This brand name is authorized in United States. It is also authorized in Australia, Austria, Croatia, Estonia, Finland, France, Ireland, Italy, Lithuania, Poland, Romania, Spain, UK.

Active ingredients

The drug EVOTAZ contains a combination of these active pharmaceutical ingredients (APIs):

1	Atazanavir UNII 4MT4VIE29P - ATAZANAVIR SULFATE
	Atazanavir is an azapeptide HIV-1 protease inhibitor (PI). The compound selectively inhibits the virus-specific processing of viral Gag-Pol proteins in HIV-1 infected cells, thus preventing formation of mature virions and infection of other cells.
	Read more about Atazanavir
2	Cobicistat UNII LW2E03M5PG - COBICISTAT
	Cobicistat is a mechanism-based inhibitor of cytochromes P450 of the CYP3A subfamily. Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as darunavir, where bioavailability is limited and half-life is shortened due to CYP3A-dependent metabolism.
	Read more about Cobicistat

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AR15		J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AR Antivirals for treatment of HIV infections, combinations
Discover more medicines within J05AR15

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10692R
EE	Ravimiamet	1692918, 1692929
ES	Centro de información online de medicamentos de la AEMPS	1151025001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	455094
FR	Base de données publique des médicaments	66190162
GB	Medicines & Healthcare Products Regulatory Agency	302259
IT	Agenzia del Farmaco	044318018, 044318020
LT	Valstybinė vaistų kontrolės tarnyba	1077588, 1077589
PL	Rejestru Produktów Leczniczych	100345078
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W61949001, W61949002
US	FDA, National Drug Code	0003-3641